Gross profit increased by 23.9% y-o-y to $15.0 million, with gross profit margin improving 1.7 percentage points y-o-y to 38.4%.
Looking ahead, Hyphens Pharma says it will be focusing on its proprietary brands, continue to seek out acquisition opportunities, boost its investment in digital initiatives and strengthen its specialty pharma portfolio.
As at 9.21am, shares in Hyphens Pharma are trading flat at 28 cents.
